[2014 Fall Life Sciences & IBB Regular Seminar]
       
         
      ▶Subject: Target discovery for therapeutic antibody
      
      ▶Speaker: Park, Young Woo, Ph.D. (Korea Research Institute of Bioscience and Biotechnology)
               
      ▶Date: 4:00PM/Nov./21(Fri)/2014
             
      ▶Place: Auditorium(1F), POSTECH Biotech Center
             
              *Abctract
           There are a number of targeted therapies currently on the market for cancer. Monoclonal antibodies (mAbs) are a promising and rapidly growing category of targeted therapeutic agents. In 2014 it is estimated that six out of global top 10 drugs are monoclonal antibodies. Most pharmaceutical companies think monoclonal antibody field as a good opportunity for their growth driving.
The advance in genomic technologies in recent years has resulted in an exponential increase in the number of potential genes and proteins available for pharmaceutical research development. The eventual maturation of genomics technology is expected to more quickly introduce increased numbers of new and more efficacious drugs into the market at lower development cost.
Antibodies are highly specific and can therefore bind and affect disease-specific targets, thereby sparing normal cells, and causing fewer toxic side-effects than cytotoxic chemotherapies. Technological developments have enabled us to produce fully human antibodies from either transgenic mice or a human antibody phage display library.
In this presentation, we will discuss human antibody scFv library and soluble receptor library for major human diseases to develop therapeutic antibodies and fusion-protein inhibitors.

      ▶Inquiry: Prof. You-Me Kim (279-0689)
            
        * This seminar will be given in English